Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.

@article{Sonkusare2005DementiaOA,
  title={Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.},
  author={S. Sonkusare and C. Kaul and P. Ramarao},
  journal={Pharmacological research},
  year={2005},
  volume={51 1},
  pages={
          1-17
        }
}
Alzheimer's disease is the fourth largest cause of death for people over 65 years of age. Dementia of Alzheimer's type is the commonest form of dementia, the other two forms being vascular dementia and mixed dementia. At present, the therapy of Alzheimer's disease is aimed at improving both, cognitive and behavioural symptoms and thereby, quality of life for the patients. Since the discovery of Alzheimer's disease by Alois Alzheimer, many pathological mechanisms have been proposed which led to… Expand
Convenient Synthesis of Memantine Hydrochloride
Alzheimer’s disease is the most common cause of dementia, affecting more than 48 million people worldwide. It has been predicted that by 2050 this figure will be more than 130 million. Alzheimer’sExpand
Endocannabinoids and Alzheimer’s disease
TLDR
Pharmacological modulation of the endocannabinoid system is emerging as a viable therapeutic target for the treatment of Alzheimer’s disease. Expand
Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions.
TLDR
A comprehensive approach to understanding AD is presented and suggestions to be considered in the development of therapeutics for it are considered. Expand
Herbal help in Alzheimer's type of cognitive disorders: A Comprehensive Review
Alzheimer’s disease is the most frequent type of life threatening dementia which is characterized by oxidative stress and inflammation induced neuronal loss, impaired energy metabolism, andExpand
Cholinesterase Inhibitors for Alzheimer Disease: Multitargeting Strategy based on Anti-Alzheimer's Drugs Repositioning.
TLDR
For the symptomatic treatment of Alzheimer's, ChEIs has been established as the most practical therapeutic target and this review represents current studies reported on the repositioning of the Food and Drug Administration (FDA)-approved ChE is as multitargeting anti-AD drugs. Expand
Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives
Alzheimer’s disease (AD) is a multifactorial disorder and apparently involves several different etiopathogenetic mechanisms. Up-to-date, there are no curative treatments or effective diseaseExpand
Alzheimer's disease and glaucoma: mechanistic similarities and differences.
TLDR
A presentation of common pathogenetic pathways associated with these disorders, including cell death mechanisms, reactive oxygen species (ROS) production, mitochondrial dysfunction and vascular abnormalities, will serve as an initiation point for further exploration. Expand
Alzheimer's disease; taking the edge off with cannabinoids?
TLDR
Cannabinoids offer a multi‐faceted approach for the treatment of Alzheimer's disease by providing neuroprotection and reducing neuroinflammation, whilst simultaneously supporting the brain's intrinsic repair mechanisms by augmenting neurotrophin expression and enhancing neurogenesis. Expand
Therapeutic approaches to Alzheimer's disease.
TLDR
Currently available drugs as well as novel therapeutic strategies, in particular those targeting amyloid and tau pathologies, are discussed. Expand
α-Synuclein and tau, two targets for dementia
TLDR
Both covalent and noncovalent inhibitors targeting alpha-synuclein and tau targeting Alzheimer's disease and Parkinson's disease with dementia are discussed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 142 REFERENCES
Treatment of Alzheimer's disease; current status and new perspectives
TLDR
Clinical features of the available cholinesterase inhibitors including their pharmacological properties, the evidence for switching from one agent to another, "head to head" studies, and the emerging evidence for the use of memantine in AD are reviewed. Expand
Medicinal chemistry approaches for the treatment and prevention of Alzheimer's disease
TLDR
The goal of the present review is the validation and an analysis of medicinal chemistry of the principles of the directed search of drugs for the treatment and prevention of AD and related neurodegenerative disorders based on systematization of the data on biochemical and structural similarities in the interaction between physiologically active compounds and their biological targets. Expand
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial
TLDR
Galantamine showed a therapeutic effect on all key areas of cognitive and non-cognitive abilities in this group of dementia patients and was well tolerated. Expand
Memantine in moderate-to-severe Alzheimer's disease.
TLDR
Antiglutamatergic treatment reduced clinical deterioration in moderate-to-severe Alzheimer's disease, a phase associated with distress for patients and burden on caregivers, for which other treatments are not available. Expand
Neuropathologic changes in Alzheimer's disease.
  • G. Wenk
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 2003
TLDR
The nature and extent of the changes associated with neural systems, possible treatment approaches, and a potential mechanism involving chronic neuroinflammation to explain the pattern of neuropathologic changes in Alzheimer's disease are summarized. Expand
Alzheimer's disease and the glutamate NMDA receptor.
TLDR
Preclinical studies and clinical trials in AD, as well as the extensive clinical use of memantine for neurodegenerative conditions in Europe since 1982 support the safety, tolerability, and efficacy of this agent. Expand
Non-cholinergic strategies for treating and preventing Alzheimer's disease.
The pathophysiology of Alzheimer's disease is complex and involves several different biochemical pathways. These include defective beta-amyloid (Abeta) protein metabolism, abnormalities ofExpand
Memantine for the treatment of dementia
TLDR
A study of the effects of memantine on moderate to severe Alzheimer's disease patients treated for 28 weeks, assessed several outcome variables, and found that memantine reduced clinical deterioration without significant adverse effects. Expand
Excitatory amino acids and Alzheimer's disease
TLDR
Circumstantial evidence raises the possibility that the EAA system may partially determine the distribution of pathology in Alzheimer's disease and may be important in producing the neurofibrillary tangles, RNA reductions and dendritic changes which characterize this devastating disorder. Expand
Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease.
TLDR
The neurodegenerative disease first described almost 100 years ago by Alois Alzheimer is predicted to be one of the major health problems of the 21st century and promising novel approaches are under way, assisted by recent advances in animal models and an increased understanding of pathophysiology. Expand
...
1
2
3
4
5
...